Previous 10 | Next 10 |
2023-10-31 09:14:03 ET More on Sarepta Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy Sarepta: Broad Label Expansion Possible With Q4 2023 Catalyst Sarepta Eyes Broadened La...
2023-10-31 08:31:19 ET Losers: Sarepta Therapeutics ( SRPT ) -43% announces topline results from EMBARK, a global pivotal study of ELEVIDYS gene therapy for Duchenne muscular dystrophy. Petmed Express PETS -26% after Q2 earning release . SELLAS Life Science...
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release preliminary financial results for the first quarter of fiscal year 2024 ended September 30, 2023, before the market open on Wednesday, N...
2023-10-25 09:25:00 ET Summary Bronte Capital is an Australian-licensed and USA SEC-registered Global Fund Manager and focuses on generating alpha from both its long and short portfolio in a unique, uncorrelated and sustainable manner. The Bronte Amalthea Fund achieved a 9.96% gai...
2023-10-12 04:19:00 ET Summary The first half of the year has been far better than expected when comparing expectations at the start of the year which was a more doom and gloom narrative along with the possibility of an earnings recession. For the first time in six quarters, earni...
2023-10-04 13:08:35 ET Summary Catalent, Inc.'s revenue and scale have suffered due to the decline in vaccine deliveries, particularly in its Biologics segment. The company reported a 3% increase in revenue for the quarter-ended June 2023, but Biologics revenue was down 37% year-o...
2023-09-24 12:00:08 ET More on COVID vaccine makers Moderna: Covid Curse Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases Novavax: Sell A Covid Bounce Barclays projects over $5B COVID booster sales in fall 2023 Vaccine makers...
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent’s Biologics segment, effective September 25, 2023. Mr. McErlane joins Catalent from...
2023-09-15 07:13:05 ET More on Catalent Seeking Alpha’s Quant Rating on Catalent Catalent gains as it enters pact with activist Elliott, to conduct business review (update) Catalent nears settlement with activist Elliott for board seats - report For fu...
Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, on September 14, 2023, it received a notice (the “NYSE Notice”) from the New Yo...
News, Short Squeeze, Breakout and More Instantly...
Expansion adds more temperature-controlled storage and dedicated space for FastChain ® demand-led supply service Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansio...
2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...